Wang XD 2011.

Methods	Country: China Setting: hospital based Aim: to study the effects of Hugu capsule in the treatment of postmenopausal osteoporosis Study design: double‐blind, placebo‐controlled, randomised controlled trial Analysis: T‐test Loss to follow‐up: not reported
Participants	Ethnicity: Chinese 122 postmenopausal osteoporosis patients enrolled: 61 in trial group, 61 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis Exclusion criteria: bone metabolic disease, endocrine disease, etc.
Interventions	Experimental: Hugu capsule (4 capsules, 3 times a day) and Caltrate (1 tablet per day), for 6 months Control: placebo capsule (4 capsules, 3 times a day) and Caltrate (1 tablet per day), for 6 months
Outcomes	BMD, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	Patients were randomly allocated
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Double‐blind
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline